Jardiance tabs from Boehringer Ingelheim and Eli Lilly now available

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Co. announced that Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States. The Food and Drug Administration approved the drug on Aug. 1 as an addition to diet and exercise to improve glycemic control or blood-glucose levels in adults with Type 2 diabetes.



“As a testament to the joint commitment by Boehringer Ingelheim and Lilly to improve care for people with diabetes, our alliance is proud to make Jardiance available so quickly following its approval by the FDA,” said Kathleen Dowd, SVP, marketing, Boehringer Ingelheim Pharmaceuticals. “We believe Jardiance is an exciting new treatment option with the potential to help many of the millions of adults with type 2 diabetes who have difficulty controlling their blood sugar levels.”



Jardiance once-daily tablets are availbale in 10-mg or 25-mg dosage strengths. The drug is not indicated for people with Type 1 diabetes or for people with diabetic ketoacidosis, the companies stated.